US · VRTX
Vertex Pharmaceuticals Incorporated
- Sector
- Healthcare · Biotechnology
- Headquarters
- Boston, MA 02210
- Website
- vrtx.com
Price · as of 2025-12-31
$423.92
Market cap 126.19B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $374.39 | -11.68% |
| Intrinsic Value(DCF) | $270.97 | -36.08% |
| Graham-Dodd Method(GD) | $146.05 | -65.55% |
| Graham Formula(GF) | $267.67 | -36.86% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $41.79 | $161.11 | $4,192.49 | $4.41 | $123.22 |
| 2012 | $52.81 | $46.86 | $4,992.25 | $2.04 | $0.00 |
| 2013 | $79.94 | $51.55 | $150.30 | $0.00 | $22.91 |
| 2014 | $124.00 | $64.00 | $0.51 | $0.00 | $131.41 |
| 2015 | $86.26 | $59.76 | $0.00 | $0.00 | $0.00 |
| 2016 | $93.98 | $71.64 | $392.39 | $2.24 | $0.00 |
| 2017 | $176.26 | $111.89 | $5,632.60 | $13.24 | $55.40 |
| 2018 | $177.26 | $142.33 | $1,554.47 | $58.47 | $243.72 |
| 2019 | $233.50 | $177.17 | $788.11 | $42.72 | $197.75 |
| 2020 | $214.33 | $253.46 | $862.22 | $81.75 | $573.98 |
| 2021 | $236.48 | $241.20 | $765.11 | $80.75 | $265.15 |
| 2022 | $287.24 | $272.50 | $511.99 | $114.93 | $328.80 |
| 2023 | $413.59 | $313.15 | $390.44 | $134.23 | $256.61 |
| 2024 | $488.29 | $255.51 | $114.07 | $49.10 | $0.00 |
| 2025 | $486.03 | $374.39 | $93.33 | $146.04 | $267.67 |
AI valuation
Our deep-learning model estimates Vertex Pharmaceuticals Incorporated's (VRTX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $374.39
- Current price
- $423.92
- AI upside
- -11.68%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$270.97
-36.08% upside
Graham-Dodd
$146.05
-65.55% upside
Graham Formula
$267.67
-36.86% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| VRTX | Vertex Pharmaceuticals In… | $423.92 | 126.19B | -12% | -36% | -66% | -37% | 31.44 | 6.66 | 10.29 | 24.47 | — | 7.25 | 85.03% | 39.43% | 32.74% | 22.54% | 28.97% | 16.24% | 0.21 | 357.95 | 2.90 | 2.24 | -0.24 | -83654.00% | 957.00% | -50413.00% | 2.57% | 0.94 | 22.83% | 0.00% | 0.00% | 1.62% | 25.53 | 38.06 | 10.07 | 12.10 |
| ARGX | argenx SE | $766.92 | 47.46B | -54% | +3,767% | -79% | +51% | 42.70 | 6.47 | 16.24 | 306.43 | — | 6.69 | 89.62% | -0.99% | 38.03% | 17.36% | -1.40% | 15.51% | 0.01 | -9.76 | 7.29 | 6.40 | -13.89 | -34767.00% | 7860.00% | -6746.00% | -0.42% | -0.12 | -9.76% | 0.00% | 0.00% | 0.00% | -1488.28 | -213.36 | 14.71 | 31.10 |
| BMY | Bristol-Myers Squibb Comp… | $62.37 | 127.01B | +7% | -50% | — | -56% | 18.03 | 6.89 | 2.64 | 11.25 | — | -5.68 | 67.65% | 26.34% | 14.63% | 40.54% | 17.21% | 7.73% | 2.55 | 8.41 | 1.26 | 1.08 | 2.54 | -17823.00% | -22.00% | -787.00% | 10.10% | 0.60 | 23.02% | 3.97% | 71.50% | 7.05% | 12.89 | 12.74 | 3.40 | 2.41 |
| CVS | CVS Health Corporation | $79.90 | 101.65B | -34% | -49% | — | -73% | 58.52 | 1.38 | 0.26 | 18.90 | — | -2.89 | 13.77% | 2.58% | 0.44% | 2.35% | 5.50% | 0.69% | 1.24 | 3.33 | 0.84 | 0.57 | 8.63 | -6202.00% | 785.00% | 2341.00% | 7.55% | 0.12 | 5.11% | 3.28% | 192.10% | 3.28% | 17.95 | 23.88 | 0.46 | 2.27 |
| GSK | GSK plc | $59.13 | 119.27B | 0% | -48% | — | -38% | 15.76 | 5.39 | 2.76 | 8.81 | 13.21 | -11.95 | 72.54% | 21.95% | 17.50% | 37.25% | 20.70% | 9.28% | 1.08 | 10.23 | 0.82 | 0.52 | 1.23 | 11935.00% | 183.00% | 6306.00% | 6.61% | 0.33 | 20.23% | 2.85% | 44.90% | 2.85% | 14.61 | 17.58 | 3.21 | 2.24 |
| HCA | HCA Healthcare, Inc. | $529.70 | 118.45B | -26% | -56% | -86% | -18% | 18.12 | -20.40 | 1.63 | 11.03 | 62.49 | -7.53 | 41.50% | 15.83% | 8.97% | -159.14% | 22.59% | 11.28% | -8.33 | 5.32 | 0.83 | 0.73 | 3.15 | 2900.00% | 708.00% | 3641.00% | 6.26% | 0.77 | 18.35% | 0.55% | 10.00% | 8.74% | 14.38 | 22.37 | 2.28 | 2.87 |
| MCK | McKesson Corporation | $987.37 | 121.87B | -46% | +187% | — | -38% | 26.01 | -43.65 | 0.25 | 17.57 | 174.88 | -6.68 | 3.48% | 1.22% | 0.92% | -172.11% | 1514.70% | 4.88% | -3.56 | 17.08 | 0.90 | 0.51 | 0.32 | 1487.00% | 1622.00% | 4409.00% | 5.77% | 0.10 | 2267.25% | 0.38% | 9.90% | 5.08% | 21.10 | 17.65 | 0.26 | 5.91 |
| MDT | Medtronic plc | $97.66 | 125.38B | — | -51% | — | -81% | 41.30 | 2.92 | 4.98 | 22.00 | — | -18.12 | 65.19% | 14.89% | 11.97% | — | — | — | 0.51 | 4.85 | 2.65 | 1.91 | 3.03 | — | — | — | 3.26% | 0.73 | — | 2.08% | 86.00% | 2.52% | 36.91 | 33.88 | 5.50 | 3.26 |
| REGN | Regeneron Pharmaceuticals… | $781.67 | 81.22B | -37% | -58% | -41% | -50% | 18.36 | 2.65 | 5.77 | 13.20 | 224.20 | 2.76 | 85.35% | 24.95% | 31.41% | 14.87% | 12.73% | 11.50% | 0.09 | 81.69 | 4.13 | 3.28 | -0.07 | 819.00% | 99.00% | 1135.00% | 4.93% | 1.14 | 16.86% | 0.45% | 8.20% | 5.36% | 21.47 | 18.83 | 5.36 | 7.62 |
| SNY | Sanofi | $48.66 | 117.52B | -6% | +222% | -59% | +2% | 12.72 | 1.39 | 2.13 | 8.95 | — | 26.05 | 72.34% | 13.58% | 16.72% | 10.50% | 6.06% | 6.02% | 0.31 | 11.73 | 1.09 | 0.28 | 1.11 | -731.00% | 549.00% | 5107.00% | 8.95% | 0.38 | 10.28% | 4.61% | 58.70% | 9.47% | 17.90 | 12.77 | 2.43 | 1.64 |
| SYK | Stryker Corporation | $387.46 | 148.28B | -24% | -56% | — | -59% | 45.57 | 6.60 | 5.89 | 25.13 | 552.53 | -57.96 | 63.96% | 19.47% | 12.92% | 15.08% | 11.08% | 7.15% | 0.66 | 8.05 | 1.89 | 1.04 | 1.72 | 825.00% | 1116.00% | 2283.00% | 2.90% | 0.65 | 13.50% | 0.87% | 39.60% | 0.87% | 32.46 | 37.05 | 6.32 | 4.53 |
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
- CEO
- Reshma Kewalramani
- Employees
- 6.1K
- Beta
- 0.32
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($270.97 ÷ $423.92) − 1 = -36.08% (DCF, example).